Sana Biotechnology, INC. (SANA) — 10-Q Filings

10-Q Filings (5)

• Sana Biotech Narrows Q3 Loss Amid R&D Cuts, Raises $109M Capital — Nov 6, 2025 Risk: high
  Sana Biotechnology, Inc. reported a net loss of $42.15 million for the three months ended September 30, 2025, a significant improvement from the $59.92 million
• Sana Biotechnology Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Sana Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations, including refere
• Sana Biotechnology Files Q3 2024 10-Q — Nov 8, 2024 Risk: medium
  Sana Biotechnology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its operati
• Sana Biotechnology Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Sana Biotechnology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including assets and liabilities, a
• Sana Biotechnology, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  Sana Biotechnology, Inc. (SANA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Sana Biotechnology, Inc. filed a 10-Q report for the quarter ended

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX